Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb;46(2):159-164.
doi: 10.1097/DSS.0000000000002029.

Cutaneous Leiomyosarcoma: A SEER Database Analysis

Neelam Sandhu  1 , Andrew P Sauvageau  2 , Adrienne Groman  3 , Paul N Bogner  4
Affiliations

Cutaneous Leiomyosarcoma: A SEER Database Analysis

Neelam Sandhu et al. Dermatol Surg. 2020 Feb.

Abstract

Background: Cutaneous leiomyosarcoma is a rare dermal neoplasm usually arising from the pilar smooth muscle. It is considered a relatively indolent neoplasm, and there is debate whether designation as sarcoma is appropriate. Owing to some conflicting data in the literature, however, its behavior warrants further clarification.

Objective: To determine the clinical behavior and demographic and pathologic characteristics of cutaneous leiomyosarcoma.

Materials and methods: The Surveillance, Epidemiology and End Results database was used to collect data on cutaneous leiomyosarcoma and 2 reference populations: cutaneous angiosarcoma (aggressive) and atypical fibroxanthoma (indolent). Demographic and oncologic characteristics were examined, and overall survivals (OS) and disease-specific survivals were compared.

Results: Leiomyosarcoma and atypical fibroxanthoma displayed lower stage (localized: 69.7% and 66.8% respectively), smaller size (<3 cm: 90.5% and 72%), and lower rates of disease-specific mortality (2.9% and 7.8%) compared with angiosarcoma. Patients with leiomyosarcoma had a 5-year disease-specific survival rate of 98% and OS rate of 85%.

Conclusion: Cutaneous leiomyosarcoma shows outcomes similar to atypical fibroxanthoma. It is nearly always indolent and should be distinguished from more aggressive cutaneous and subcutaneous sarcomas. Clear communication of the biologic potential may be best achieved using alternate diagnostic terminology such as "atypical intradermal smooth-muscle neoplasm."

PubMed Disclaimer

References

    1. Aneiros-Fernandez J, Antonio Retamero J, Husein-Elahmed H, Ovalle F, et al. Primary cutaneous and subcutaneous leiomyosarcomas: evolution and prognostic factors. Eur J Dermatol 2016;26:9–12.
    1. Hall BJ, Grossmann AH, Webber NP, Ward RA, et al. Atypical intradermal smooth muscle neoplasms (formerly cutaneous leiomyosarcomas): case series, immunohistochemical profile and review of the literature. Appl Immunohistochem Mol Morphol 2013;21:132–8.
    1. Massi D, Franchi A, Alos L, Cook M, et al. Primary cutaneous leiomyosarcoma: clinicopathological analysis of 36 cases. Histopathology 2010;56:251–62.
    1. Kraft S, Fletcher CD. Atypical intradermal smooth muscle neoplasms: clinicopathologic analysis of 84 cases and a reappraisal of cutaneous “leiomyosarcoma.” Am J Surg Pathol 2011;35:599–607.
    1. Ortins-Pina A, Soares-de-Almeida L, Rutten A. Primary cutaneous vascular leiomyosarcoma: a rare subtype of leiomyosarcoma of the skin. J Cutan Pathol 2018;45:639–41.

LinkOut - more resources